Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2009

View Archived Issues

Influenza A/H1N1 vaccine evaluated in a series of phase II trials by sanofi-aventis and NIAID

Novel oncolytic compounds claimed by Korean scientists

Hematologic improvement seen with Telintra in myelodysplastic syndrome patients

Data from phase III studies show efficacy of roflumilast in chronic obstructive pulmonary disease

Peregrine reports advances in bavituximab clinical program

MediGene obtains marketing authorization for Veregen in Germany

Vical receives USD 2.5 million payment for funding of Allovectin-7 trial

Biovista reports results from preclinical trial of BVA-201 in multiple sclerosis

PRO-040201 to be evaluated by Tekmira in phase I trial in patients with hypercholesterolemia

Chelsea Therapeutics achieves target enrollment in second pivotal phase III droxidopa trial

Intranasal influenza vaccination with NB-1008 safe in rabbits

Sulopenem and its prodrug evaluated in healthy volunteers

PH-10 aqueous hydrogel to be assessed in plaque psoriasis in phase II trial

AstraZeneca discloses Janus kinase inhibitors for the treatment of cancer

Anti-staphylococcal activity of novel antimicrobial XF-70 described during the ICAAC meeting

Cleveland BioLabs and Zhejiang Hisun enter license agreement for CBLB-612

BACE1 inhibitors for the treatment of cognitive disorders discovered by Janssen

NPY Y5 antagonists in development at GSK for the treatment of eating disorders

Chinese scientists describe a novel series of anti-HIV agents

Oramed commences human clinical trials for oral GLP-1 analogue

FDA Advisory Committee votes favorably for Cervarix

ImmunoCellular Therapeutics enters into agreement with Roche for ICT-69 antibody

Xoma and Arana Therapeutics form antibody discovery collaboration

Galapagos initiates second phase I GLPG-0259 trial in rheumatoid arthritis

Cumberland launches intravenous ibuprofen in the U.S. for pain and fever

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...